Nyxoah SA（NYXH）の株式分析NYXHNyxoah SA

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin. It operates in the Healthcare sector.

Nyxoah SA is not a strong buy right now due to significant recent losses and mixed analyst ratings. The current price is $1.60, with a one-year change of -72.88%, indicating a steep decline. Although the company reported a 21% revenue growth in Q2 2026, the net income remains negative at -32,964,000 EUR for the same quarter, which raises concerns about profitability. The RSI is at 51.048, suggesting a neutral momentum, and the forward P/E ratio is not applicable due to negative earnings, indicating a lack of clear valuation metrics. The main risk is the high debt-to-equity ratio of 72.18%, which could impact financial stability.